deliver the immune response they wish they had
For as long as measles has threatened human life, the most vulnerable among us — the newborn, the pregnant, the immunocompromised — have had no recourse beyond hope. Now, researchers at La Jolla Institute for Immunology have mapped the precise architecture of human antibodies capable of neutralizing the measles virus, offering the first real prospect of a treatment in a moment when declining vaccination rates have quietly dismantled the communal shield that once protected those who could not protect themselves.
- Measles is circulating again in communities where vaccination rates have fallen below the threshold needed to protect those who cannot be immunized — infants, pregnant women, cancer patients — leaving them genuinely exposed to a potentially lethal virus.
- The only existing tool, a live-virus vaccine, is itself forbidden to the very people most at risk, and no measles-specific treatment has ever existed — leaving doctors with nothing but symptom management and uncertainty.
- Scientists isolated antibodies from a single vaccinated donor, used atomic-resolution imaging to understand exactly how they disable the virus, and confirmed in animal models that one antibody — 3A12 — reduced circulating virus to undetectable levels.
- A 500-fold reduction in viral load in earlier rodent studies signals that these antibodies are not merely promising but exceptionally potent, roughly 100 times more effective than previously reported comparable molecules.
- The path forward leads toward clinical trials and monoclonal antibody therapies — laboratory-manufactured immune responses that could be infused into high-risk patients, delivering protection their own bodies cannot generate.
Measles has returned to American hospitals, and the people most endangered — infants too young for vaccination, pregnant women, those undergoing chemotherapy — have no medical defense. Researchers at La Jolla Institute for Immunology have now identified a potential one: human antibodies potent enough to become the first treatment ever designed specifically to fight measles infection.
Using cryo-electron microscopy to photograph molecules at atomic resolution, a team led by Erica Ollmann Saphire examined blood from a single vaccinated volunteer and isolated antibodies that bind to two critical targets on the virus. What they found was remarkable — these antibodies were roughly 100 times more effective than comparable molecules previously reported. Their mechanism is precise: they lock the virus's fusion protein in place, preventing the unfolding that allows measles to penetrate a human cell.
Animal testing confirmed the power of this approach. Cotton rats exposed to measles and treated within 24 to 48 hours showed significant viral load reductions across all four lead antibodies. One, called 3A12, rendered circulating virus completely undetectable. Earlier studies had already shown a 500-fold reduction in viral load — a dramatic suppression by any measure.
The stakes are sharpened by a troubling backdrop. Vaccination rates have eroded herd immunity across many regions, and the measles vaccine itself — a live weakened virus — remains off-limits for immunocompromised patients, pregnant women, and children under 12 months. There is currently no measles-specific therapy at all. Monoclonal antibody treatments already exist for other infections, including respiratory syncytial virus in infants, and the same model could work here.
Saphire's team has now provided the blueprint — which antibodies work, how they bind, and why they succeed. Moving from animal studies to human trials, these discoveries could one day give the most vulnerable populations something that has never existed before: a fighting chance against a virus that has always found them first.
Measles has returned to American hospitals and clinics with a vengeance, and the people most at risk—infants too young for vaccination, pregnant women, those undergoing chemotherapy—have no medical shield. Now researchers at La Jolla Institute for Immunology have identified a potential one: human antibodies so potent they could become the first treatment ever designed specifically to fight measles infection.
The work began with a simple question: could scientists capture the precise way human antibodies neutralize measles virus? Using cryo-electron microscopy, a technique that freezes molecules in place and photographs them at atomic resolution, researchers led by Erica Ollmann Saphire examined blood from a vaccinated volunteer. From that single sample, they isolated antibodies that latch onto two critical targets on the virus—the fusion protein and an attachment protein called H. When the team photographed these antibodies bound to measles virus in three dimensions, they discovered something striking: the antibodies were exceptionally potent, roughly 100 times more effective than comparable molecules previously reported in the field.
Measles virus is a shape-shifter. When it encounters a human cell, the virus unfolds to reveal machinery that fuses with the cell membrane, allowing infection to begin. The new antibodies work by locking the fusion protein in place, preventing that critical unfolding. The virus becomes trapped in its original shape, unable to penetrate the cell. This mechanism emerged from the detailed 3D images the team captured—a roadmap showing exactly where the virus is vulnerable to attack.
The real test came in animals. Collaborators at Ohio State University used cotton rats to model measles infection, administering the antibodies either before exposure or within 24 to 48 hours after the virus entered the body. All four lead antibodies reduced viral load significantly. One antibody, called 3A12, proved especially striking: it rendered circulating virus completely undetectable. In earlier rodent studies, an infusion of these antibodies produced a 500-fold reduction in viral load—a dramatic suppression of the infection.
The urgency behind this work is unmistakable. Vaccination rates have fallen in recent years, eroding the community protection that once kept measles at bay. Herd immunity—the threshold where enough people are vaccinated to protect those who cannot be—has crumbled in many regions. Meanwhile, the measles vaccine itself, though safe and effective, contains a live weakened virus, making it off-limits for anyone with a compromised immune system. Pregnant women cannot receive it. Children undergoing cancer treatment cannot receive it. Infants must wait until age 12 months, and most American children aren't fully protected until age six. These vulnerable populations now face genuine risk in a world where measles is circulating again.
Currently, there is no measles-specific therapy. Doctors can only manage symptoms and hope the immune system prevails. Monoclonal antibody treatments—laboratory-made copies of a single, highly effective antibody—already exist for other infections. Infants receive them annually to prevent respiratory syncytial virus. The same approach could work for measles, if the right antibodies can be manufactured and delivered in time.
Saphire and her team have now provided the blueprint. They know which antibodies work, how they bind to the virus, and why they succeed. The next phase will be moving from animal studies toward human trials, transforming these laboratory discoveries into actual medicine. For the millions of people who cannot be vaccinated, the possibility of receiving an infusion that delivers the immune response they cannot generate themselves represents something that did not exist before: a fighting chance.
Notable Quotes
These antibodies work as prophylaxis to protect from initial infection and they work after viral exposure as a treatment to fight measles infection.— Erica Ollmann Saphire, LJI Professor, President & CEO
We found that these antibodies are exceptionally potent. Two orders of magnitude better than comparable molecules reported at conferences.— Dawid Zyla, LJI Instructor and study co-first author
The Hearth Conversation Another angle on the story
Why does this matter now, specifically? Measles has been around for centuries.
Because we stopped vaccinating at high enough rates. For decades, herd immunity protected the people who couldn't be vaccinated. That shield is gone. Now those vulnerable people—infants, pregnant women, immunocompromised patients—are exposed.
And the vaccine itself can't help them?
The measles vaccine uses a live weakened virus. If your immune system is already compromised, introducing even a weakened virus is dangerous. You can't give it to pregnant women or people on chemotherapy. Infants have to wait a year. So there's a window—sometimes a long one—where you're unprotected.
What makes these antibodies different from what existed before?
There was nothing before. No measles-specific treatment at all. These antibodies are also unusually potent—about 100 times more effective than anything researchers had seen previously. And they work both as prevention and as treatment after exposure.
How did they find them?
From one vaccinated person's blood. That person's immune system had already learned to fight measles, so their antibodies were already refined and effective. The researchers isolated the best ones and photographed them binding to the virus at atomic resolution.
And the animal tests showed what?
Complete suppression in some cases. One antibody made the virus undetectable in the bloodstream. In other tests, viral load dropped 500-fold. These aren't marginal improvements.
What's the timeline to actual patients?
That's the hard part. They've proven the concept in animals. Now comes human trials, manufacturing at scale, regulatory approval. Years, probably. But for the first time, there's a real path forward for people who have no other options.